INTRODUCTION {#s1}
============

Hepatocellular carcinoma (HCC) is the most frequent histological form of primary liver cancer \[[@R1]\] and the sixth most common cancer in the world \[[@R2]\]. HCC mortality ranks third among all cancers worldwide and causes 600,000 deaths per year \[[@R2]\]. Metastasis is the major risk factor for long-term survival of patients with post-hepatectomy HCC, and it contributes to the high recurrence rate of HCC \[[@R3], [@R4]\]. Lymph node metastasis (LNM) occurs in approximately 10.0 % of HCC patients during the follow-up period after hepatectomy \[[@R5]\], whereas the LNM rate is estimated as 33.8 % in HCC patients with extrahepatic metastasis \[[@R6]\]. Although LNM of HCC is reported to be sensitive to external beam radiotherapy \[[@R7]\], the prognosis of LNM patients is worse than that of patients without LNM \[[@R8]\]. Therefore, it is important to establish a predictive model and identify molecular markers for LNM to accurately assess the LNM risk in HCC patients. The factors involved in LNM of HCC are poorly documented, especially microRNAs (miRNAs).

MiRNAs are a class of small, non-coding, and 20-22 nucleotides long RNAs, which are important regulators of gene expression \[[@R9]\]. Recent studies report that specific miRNAs contribute to LNM in several cancers. MiR-31 promotes LNM in lung adenocarcinoma (ADC) \[[@R10]\]. Aberrant miRNAs, including high-expression miR-185-5p and miR-542-5p and low-expression miR-339-5p and miR-3923, contribute to LNM of breast cancer \[[@R11]\]. Yigit and coauthors confirmed that miR-10b targeting prevented and arrested LNM in breast cancer \[[@R12]\].

The miRNAs responsible for LNM in HCC are largely unknown. If miRNA expression profiling could be used to identify HCC patients at high risk for LNM, the high-risk population could receive prophylactic radiotherapy for regional lymph nodes. So, it might reduce LNM incidence and prolong overall survival time for patients. In this study, we established tissue microarrays (TMAs) and performed in situ hybridization (ISH) to discover novel and annotated miRNAs, which are associated with LNM in HCC patients. We identified significant miRNA signatures and developed a novel miRNA-based prediction model to identify HCC patients at high risk for LNM.

RESULTS {#s2}
=======

Expression of in situ hybridization biomarkers in tissue microarrays {#s2_1}
--------------------------------------------------------------------

Figure [1](#F1){ref-type="fig"} shows that miR-31 and miR-92a expression was identified in the cytoplasm and in the nucleus, whereas miR-145 and miR-10b expression was localized primarily to the cytoplasm of tumor cells. In the training cohort of 192 patients, positive miR-145 expression was detected in 47 patients (24.5 %), positive miR-31 expression was detected in 35 patients (18.2 %), positive miR-92a expression was detected in 55 patients (28.6 %), and high miR-10b expression was detected in 59 patients (30.7 %). In the validation cohort of 209 patients, positive miR-145 expression was detected in 54 patients (25.8 %), positive miR-31 expression was detected in 39 patients (18.7 %), positive miR-92a expression was detected in 66 patients (31.6 %), and high miR-10b expression was detected in 65 patients (31.1 %).

![Expression of miR-145, miR-31, miR-92a, and miR-10b in hepatocellular carcinoma tissue microarrays\
Representative miR-145, miR-31, miR-92a, and miR-10b staining. Negative intratumoral expression of miR-145 **A.** positive intratumoral expression of miR-145 **B.** negative intratumoral expression of miR-31 **C.** positive intratumoral expression of miR-31 **D.** negative intratumoral expression of miR-92a **E.** positive intratumoral expression of miR-92a **F.** low intratumoral expression of miR-10b **G.** and high intratumoral expression of miR-10b **H.** Magnification × 200.](oncotarget-07-3587-g001){#F1}

Significant predictors of lymph node metastasis {#s2_2}
-----------------------------------------------

Detailed characteristics of all patients analyzed in this study are presented in Table [1](#T1){ref-type="table"}. The following 19 clinicopathological factors were analyzed in the training cohort: age, gender, HBsAg, hepatitis C virus antibody (HCV-Ab), alpha-fetoprotein (AFP), alanine aminotransferase (ALT), gamma-glutamyl transferase (γ-GT), liver cirrhosis, Child-Pugh score, tumor differentiation, tumor size, tumor number, tumor encapsulation, vascular invasion, Barcelona Clinic Liver Cancer (BCLC) stage, miR-145, miR-31, miR-92a, and miR-10b. Table [2](#T2){ref-type="table"} summarizes the association of these clinicopathological factors with the LNM status of HCC patients in the training cohort, which were determined by univariate analysis. These significant variables were adopted for multivariate analysis, which indicated that the following five independent variables could significantly predict the LNM risk in HCC: vascular invasion (*P* = 0.001), BCLC stage (*P* = 0.018), miR-145 (*P* = 0.014), miR-31 (*P* = 0.006), and miR-92a (*P* = 0.034) (Table [3](#T3){ref-type="table"}). We also identified miR-145, miR-31 and miR-92a were correlated with vascular invasion and BCLC stage ([Supplementary Tables S1 and S2](#SD1){ref-type="supplementary-material"}).

###### Clinicopathological characteristics of the study population

  Variable                Training cohort   Validation cohort                                      
  ----------------------- ----------------- ------------------- ---- ------------ ----- ----- ---- ------------
  Age                                                                                              
   ≤ 51                   94                82                  12   0.742        102   88    14   0.220
   \>51                   98                87                  11                107   98    9    
  Gender                                                                                           
   male                   168               149                 19   0.674        182   163   19   0.728
   female                 24                20                  4                 27    23    4    
  HBsAg                                                                                            
   negative               53                46                  7    0.746        54    49    5    0.634
   positive               139               123                 16                155   137   18   
  HCV-Ab                                                                                           
   negative               188               165                 23   0.457        205   182   23   0.479
   positive               4                 4                   0                 4     4     0    
  AFP                                                                                              
   ≤20                    49                40                  9    0.111        57    49    8    0.391
   \>20                   143               129                 14                152   137   15   
  ALT                                                                                              
   ≤40                    112               100                 12   0.523        121   108   13   0.888
   \>40                   80                69                  11                88    78    10   
  γ-GT                                                                                             
   ≤50                    69                62                  7    0.558        74    68    6    0.322
   \>50                   123               107                 16                135   118   17   
  Liver cirrhosis                                                                                  
   no                     31                27                  4    1.000        33    28    5    0.599
   yes                    161               142                 19                176   158   18   
  Child-Pugh score                                                                                 
   A                      190               167                 23   0.601        207   184   23   0.618
   B                      2                 2                   0                 2     2     0    
  Tumor differentiation                                                                            
   I--II                  140               124                 16   0.700        153   135   18   0.562
   III--IV                52                45                  7                 56    51    5    
  Tumor size, cm                                                                                   
   ≤5                     98                87                  11   0.742        108   95    13   0.622
   \>5                    94                82                  12                101   91    10   
  Tumor number                                                                                     
   single                 139               123                 16   0.746        153   138   15   0.359
   multiple               53                46                  7                 56    48    8    
  Tumor encapsulation                                                                              
   complete               98                83                  15   0.147        107   93    14   0.325
   none                   94                86                  8                 102   93    9    
  Vascular invasion                                                                                
   no                     165               154                 11   \< 0.001\*   164   152   12   0.003\*
   yes                    27                15                  12                45    34    11   
  BCLC stage                                                                                       
   0-A                    169               156                 13   \< 0.001\*   177   166   11   \< 0.001\*
   B-C                    23                13                  10                32    20    12   
  MiR-145                                                                                          
   negative               145               138                 7    \< 0.001\*   155   146   9    0.001\*
   positive               47                31                  16                54    40    14   
  MiR-31                                                                                           
   negative               157               147                 10   \< 0.001\*   170   166   4    \< 0.001\*
   positive               35                22                  13                39    20    19   
  MiR-92a                                                                                          
   negative               137               132                 5    \< 0.001\*   143   141   2    \< 0.001\*
   positive               55                37                  18                66    45    21   
  MiR-10b                                                                                          
   low expression         133               117                 16   0.974        144   130   14   0.378
   high expression        59                52                  7                 65    56    9    

HBsAg hepatitis B surface antigen, HCV-Ab hepatitis C virus antibody, AFP a-fetoprotein, ALT alanine aminotransferase, γ-GT γ-glutamyl transferase, BCLC stage Barcelona Clinic Liver Cancer stage,\* significance values.

###### Univariate analysis of clinicopathological factors associated with lymph node metastasis of hepatocellular carcinoma in the training cohort

  Clinicopathological factors   Univariate                    
  ----------------------------- ------------ ---------------- ------------
  Age                                                         
   ≤ 51                         1            0.402-3.479      0.761
   \>51                         1.182                         
  Gender                                                      
   male                         1            0.383-1.970      0.736
   female                       0.868                         
  HBsAg                                                       
   negative                     1            0.344-2.047      0.701
   positive                     0.840                         
  HCV-Ab                                                      
   negative                     1            0.000--1.094E7   0.757
   positive                     0.048                         
  AFP                                                         
   ≤20                          1            0.255-1.364      0.217
   \>20                         0.590                         
  ALT                                                         
   ≤40                          1            0.637-3.286      0.337
   \>40                         1.447                         
  γ-GT                                                        
   ≤50                          1            0.963-5.929      0.060
   \>50                         2.389                         
  Liver cirrhosis                                             
   no                           1            0.281-2.438      0.731
   yes                          0.827                         
  Child-Pugh score                                            
   A                            1            0.000-4.640E4    0.666
   B                            0.048                         
  Tumor differentiation                                       
   I--II                        1            0.431-2.574      0.910
   III--IV                      1.053                         
  Tumor size, cm                                              
   ≤5                           1            0.634-3.269      0.383
   \>5                          1.440                         
  Tumor number                                                
   single                       1            0.458-2.710      0.811
   multiple                     1.115                         
  Tumor encapsulation                                         
   complete                     1            0.187-1.049      0.064
   none                         0.443                         
  Vascular invasion                                           
   no                           1            4.577-24.284     \< 0.001\*
   yes                          10.543                        
  BCLC stage                                                  
   0-A                          1            1.050-6.765      0.039\*
   B-C                          2.665                         
  MiR-145                                                     
   negative                     1            1.123-5.777      0.025\*
   positive                     2.547                         
  MiR-31                                                      
   negative                     1            3.164-16.657     \< 0.001\*
   positive                     7.260                         
  MiR-92a                                                     
   negative                     1            2.214-13.137     \< 0.001\*
   positive                     5.393                         
  MiR-10b                                                     
   low expression               1            0.334-1.981      0.650
   high expression              0.814                         

HBsAg hepatitis B surface antigen, HCV-Ab hepatitis C virus antibody, AFP a-fetoprotein, ALT alanine aminotransferase, γ-GT γ-glutamyl transferase, BCLC stage Barcelona Clinic Liver Cancer stage, CI, confidence interval. \* significance values.

###### Multivariate analysis of significant clinicopathological factors associated with lymph node metastasis of hepatocellular carcinoma in the training cohort

  Clinicopathological factors   Multivariate                          
  ----------------------------- -------------- ------- -------------- ---------
  Vascular invasion                                                   
   no                                          1       2.010-13.199   0.001\*
   yes                          11.665         5.151                  
  BCLC stage                                                          
   0--A                                        1       1.204-6.984    0.018\*
   B--C                         5.632          2.899                  
  MiR-145                                                             
   negative                                    1       1.295-10.176   0.014\*
   positive                     6.011          3.630                  
  MiR-31                                                              
   negative                                    1       1.427-8.613    0.006\*
   positive                     7.485          3.506                  
  MiR-92a                                                             
   negative                                    1       1.098-10.833   0.034\*
   positive                     4.496          3.449                  

Variables were adopted for their prognostic significance on univariate analysis.

BCLC stage Barcelona Clinic Liver Cancer stage, CI confidence interval, \* significance values.

Constructing the miRNA-based prediction model of lymph node metastasis in hepatocellular carcinoma {#s2_3}
--------------------------------------------------------------------------------------------------

The miRNA-based prediction model was constructed as follows using multivariate analysis. Each chi-square (χ2) value was divided by the minimum multivariate analysis χ^2^ value of 4.496 to obtain a simple risk score for each significant variable according to its relative contribution to the multivariate analysis model (Table [4](#T4){ref-type="table"}). The total risk score of every patient was the aggregate of all simple risk scores, ranging from 0 to 8 in both the training and the validation cohorts. The cutoff point of 4 for both cohorts was the best determinant to discriminate patient categories for low-risk and high-risk LNM groups using the χ^2^ test for linear trend.

###### Components of the lymph node metastasis prediction score

  Factor              Score
  ------------------- -------
  Vascular invasion   
   no                 0
   yes                2.6
  BCLC stage          
   0-A                0
   B-C                1.3
  MiR-145             
   negative           0
   positive           1.3
  MiR-31              
   negative           0
   positive           1.7
  MiR-92a             
   negative           0
   positive           1

BCLC stage Barcelona Clinic Liver Cancer stage, Scores ≤4 indicates low risk and \>4 indicates high risk.

Using the score of 4 as a cutoff point in the training cohort of 192 patients, 176 (91.7 %) and 16 (8.3 %) patients were in the low-risk and high-risk groups, respectively. In the low-risk and high-risk groups of the training cohort, 10/176 (5.7 %) and 13/16 (81.3 %) patients developed LNM (*P* \< 0.05). The three-miRNA-based prognostic model sensitivity was 73.9 % and specificity was 79.4 % over 5 years and the area under the receiver operating characteristic (ROC) curve (AUC) was 0.906 (95 % CI, 0.842--0.969; *P* \< 0.001), which indicates good reliability and validity ([Supplementary Figure S1A](#SD1){ref-type="supplementary-material"}). The 1- and 2-year cumulative LNM rates in the high-risk group were 78.1 and 85.4 %, respectively, whereas these values were 3.7 and 4.8 %, respectively, in the low-risk group. Patients in the high-risk group were found to have higher LNM rates ([Supplementary Figure S1B](#SD1){ref-type="supplementary-material"}). The 5-year positive and negative predictive values of the LNM prediction model were 32.8 and 95.7 %, respectively. Cox regression analysis determined that the LNM hazard ratio for high-risk versus low-risk groups was 32.071 (95 % CI, 12.599--81.636; *P* \< 0.001).

Real time qRT-PCR verification of miRNAs for LNM in HCC {#s2_4}
-------------------------------------------------------

Real time quantitative reverse transcriptase PCR(qRT-PCR) was performed to quantify miRNAs levels in formalin-fixed, paraffin-embedded (FFPE) specimens of 192 HCC patients. The following 19 clinicopathological factors analyzed in the training cohort were as follows: age, gender, HBsAg, hepatitis C virus antibody (HCV-Ab), AFP, ALT, γ-GT, liver cirrhosis, Child-Pugh score, tumor differentiation, tumor size, tumor number, tumor encapsulation, vascular invasion, BCLC stage, miR-145, miR-31, miR-92a, and miR-10b. Univariate analyses indicated that miR-145 (*P* = 0.036), miR-31 (*P* = 0.008), miR-92a (*P* = 0.025), vascular invasion (*P* \< 0.001), and BCLC stage (*P* = 0.039) were associated with LNM in HCC patients. And miR-145 (*P* = 0.029), miR-31 (*P* = 0.018), miR-92a (*P* = 0.043), vascular invasion (*P* = 0.007), and BCLC stage (*P* = 0.024) were independent risk factors for LNM prediction in HCC patients by multivariate analyses.

Validating the prognostic value of the miRNA-based model {#s2_5}
--------------------------------------------------------

The prognostic value of the miRNA-based model was validated using an independent validation cohort of 209 patients and the cutoff point of 4. The results indicated that 190/209 (90.9 %) and 19/209 (9.1 %) patients were categorized as low risk and high risk, respectively, in the validation cohort. In the low-risk and high-risk groups of the validation cohort, 11/190 (5.8 %) and 12/19 (63.2 %) patients developed LNM, respectively. Analysis of the validation cohort by ROC curve proved that the miRNA prediction model could predict LNM in HCC patients, with very high AUC of 0.860 (95 % CI, 0.773--0.948; *P* \< 0.001) ([Supplementary Figure S1C](#SD1){ref-type="supplementary-material"}). The 5-year sensitivity and specificity of the prediction model were 69.6 and 80.2 %, respectively. The positive and negative values of the cutoff score for predicting LNM in HCC were 30.3 and 95.5 %, respectively, over 5 years.

Kaplan--Meier and log-rank tests were applied for analysis of time-to-LNM. The 1- and 2-year cumulative LNM rates in the high-risk category were 38.6 and 71.2 %, respectively, whereas these values were 4.5 and 11.7 %, respectively, in the low-risk category. Patients in the high-risk group had a higher risk for developing LNM than patients in the low-risk group ([Supplementary Figure S1D](#SD1){ref-type="supplementary-material"}). The Cox regression analysis hazard ratio for developing LNM of the high-risk versus low-risk groups was 11.751 (95 % CI, 5.110--27.021; *P* \< 0.001).

DISCUSSION {#s3}
==========

The incidence of LNM in extrahepatic metastases of HCC is 33.8 % \[[@R6]\], which contributes to the high mortality and poor prognosis of patients with HCC. However, an accurate model that can predict the LNM risk for patients with HCC has not been available. The LNM status depends primarily on LN biopsy, which may increase distant metastatic rates and reduce survival \[[@R21]\]. PET and CT analyses have low sensitivity for detecting tumor-positive small LNs \<1 cm \[[@R22]\]. Therefore, the discovery of molecular markers to accurately assess the risk of LN involvement is of great importance. Aberrant forms of miRNAs have been reported in many cancer types, and considerable attention is focused on understanding the role of miRNAs in cancer development \[[@R23]--[@R25]\]. MiRNAs appear to have potential as molecular markers that can be developed to assess the LNM risk in many cancers \[[@R26]--[@R29]\]. In the current study, we sought to identify novel miRNAs that predict LNM in HCC.

We constructed and then validated a novel tool based on three miRNAs to predict LNM development for patients with HCC after hepatectomy. Our miRNA prediction model incorporates the following five factors: vascular invasion, BCLC stage, miR-145, miR-31, and miR-92a. Vascular invasion and BCLC stage are known prognostic factors for HCC \[[@R30], [@R31]\]. MiR-145 is known to promote LNM in colorectal cancer (CRC) \[[@R32]\]. The increased expression of heat shock protein 27 (Hsp-27), an up-regulated target of miR-145, is responsible for LNM in CRC \[[@R32]\]. MiR-31 promotes LNM in lung ADC through the activation of ERK1/2 signaling \[[@R10]\]. MiR-92a targeted suppressed E-Cadherin (CDH1) expression to promote LNM in esophageal squamous cell carcinoma \[[@R33]\]. And we are going to investigate the molecular mechanism of abnormal miRNAs expression associated with LNM in HCC by a large prospective research. It may have a little limitation for that some potential miRNAs may be not included in the study. We are going to screen significant miRNAs on a large scale through miRNA microarray in future research to enrich and perfect the microRNA-based prediction model for LNM in HCC.

To our knowledge, the significance of such a prediction model has not been unveiled in HCC, especially with respect to LNM. The miRNA-based prediction model effectively and accurately classifies post-hepatectomy HCC patients into groups with low risk and high risk of developing LNM. This model could be implemented for routine clinical use, and serve as a valuable tool for determining optimal treatment strategies for HCC patients. Traditional approaches include palliative radiotherapy after LNM. However, our model can identify high-risk HCC patients in advance, just after hepatectomy, which may help to guide the therapeutic strategy. These high-risk patients can be treated with prophylactic radiotherapy for regional lymph nodes during the earliest stages before LNM develops. This strategy could replace the current passive palliative treatment with active preventative treatment to suppress LNM development. Thus, the LNM incidence in HCC can be reduced, and the life quality and survival of patients can be improved. This predictive model also may provide new therapeutic targets and facilitate decisions regarding individualized clinical therapies.

In summary, the results confirm that our miRNA-based model is a good prognostic system to predict LNM in HCC patients. The predictive model is reliable and accurate for predicting LNM development in HCC patients. Further studies of larger cohorts are required, and the model should be validated in a prospective study. The mechanisms of abnormal miRNA expression in HCC are currently unclear, which requires investigation in future research.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

Investigation had been approved by the Ethical Review Board of Zhongshan Hospital, Fudan University. Informed consent had been obtained from all participants included in this study.

Patients and tissue specimens {#s4_2}
-----------------------------

All patients with HCC included in this study were diagnosed based on pathology. Patients with a history of other solid tumors were excluded from the study. None of the patients had distant metastasis before surgery, nor had they received anticancer therapy before surgery. All patients received chest radiography and abdominal ultrasonography examinations before surgery, and patients with extrahepatic metastasis were excluded from the study. Bone scanning was performed if bone pain was reported. If extrahepatic metastasis was suspected, computed tomography (CT) and/or magnetic resonance imaging (MRI) was performed to verify the occurrence of extrahepatic metastasis. Suitable FFPE tissue samples, complete clinicopathological examinations, and follow-up data were available for all patients. The tumor stage was defined in accordance with the BCLC staging system (2010 version). The histological grade of tumor differentiation was determined by the Edmondson grading system. Liver function was classified by the Child-Pugh scoring system. Tumor size depended on the maximum diameter of the tumor specimen. The extent of vascular invasion was identified by microscopic examination of the resected specimen.

The retrospective study was performed in two independent cohorts. The training cohort consisted of 192 consecutive HCC patients who underwent hepatectomy (all performed by the same surgical team) at the Liver Cancer Institute, Fudan University, from October 1999 to January 2006. The training cohort was used to develop a predictive model for LNM in HCC. The validation cohort consisted of 209 patients with HCC, who were recruited from August 2000 to May 2006. All patients in the validation cohort underwent hepatectomy by a different surgical team at the same institution. All patients in the training cohort were observed until December 2012, with a median follow-up time of 52.8 months (range 2.9-125.7 months). The follow-up cutoff time for the validation cohort was August 2012, with a median follow-up time of 53.7 months (range 3.8-128.6 months). During the follow-up period, 23 patients (12.0 %) in the training cohort and 23 patients (11.0 %) in the validation cohort developed LNM.

Follow-up assessments {#s4_3}
---------------------

All patients received follow-up evaluations every 3 months after hepatectomy; each follow-up evaluation performed physical examinations and collected history documentation. Each follow-up examination included ultrasonographic examination of the liver and abdominal LNs; laboratory tests including liver function, AFP, ALT, and γ-GT; and evaluation of hematologic parameters. These examinations were performed by doctors who were blind to the study. Chest radiography was performed at 6-month intervals and a bone scan was performed annually. CT scanning or MRI was performed immediately when LNM was suspected. Metastatic LNs were indicated by one of the following: hypoechoic masses on ultrasonography, a central hypodensity region bordered by a faint hyperdensity rim on contrast CT scanning, or high signal intensity on T2-weighted MRI \[[@R5]\]. When a diagnosis of LNM was confirmed, the metastatic LNs received external beam radiotherapy \[[@R7]\]. Other recurrent foci were treated with radiotherapy, interventional therapy, or surgery.

Tissue microarray construction and analysis {#s4_4}
-------------------------------------------

TMAs were constructed as described previously \[[@R13]\]. We constructed TMA slides (in collaboration with Biochip Company, Ltd., Shanghai, China) using HCC samples from 192 consecutive HCC patients in the training cohort and 209 consecutive HCC patients in the validation cohort. Slides stained with hematoxylin and eosin was screened to identify optimal intratumoral tumor tissue for analysis. Two cores with dimensions of 1.0 mm were punched from non-necrotic areas of tumor foci in the patient paraffin blocks. Sections (4-μm thickness) of the resulting TMA blocks were made using standard techniques.

In situ hybridization analysis {#s4_5}
------------------------------

ISH assays were performed with locked nucleic acid (LNA)-modified, 5′-digoxigenin (DIG)-labeled probes for mature human miRNAs (Exiqon, Vedbaek, Denmark). The following LNA primer sets were used: miR-145, 5′-AGGGATTCCTGGGAAAACTGGAC-3′; miR-31, 5′-AGCTATGCCAGCATCTTGCCT-3′; miR-92a, 5′-ACAGGCCGGGACAAGTGCAATA-3′; and miR-10b, 5′-CACAAATTCGGTTCTACAGGGTA-3′. Hybridization was performed using 4-μm sections of FFPE tissue. Briefly, slides were dewaxed, rehydrated, and acetylated with 0.25 % acetic anhydride. Then, sections were prehybridized in hybridization solution (Exiqon, Vedbaek, Denmark) for 1 h at 55°C. Hybridization was performed with 20 μl of a diluted solution (1:500) of the corresponding LNA probes overnight at 56°C. Slides were then washed once with 5 × SSC buffer followed by two washes with 0.2 × SSC buffer at 60°C. Chromogenic detection of signals was performed using an anti-DIG antibody (Zytovision, Germany) at 37°C and alkaline phosphatase-conjugated secondary antibody (Zytovision, Germany) according to the manufacturer\'s instructions.

Evaluation methods for determining miRNA expression {#s4_6}
---------------------------------------------------

Tissue sections were blindly examined by two experienced pathologists using an Olympus BX51 microscope (Olympus BX51, CCD: DP71, Japan). The average of the two scores was calculated. The chromogenic intensity of miR-145 expression was visually semi-quantified as follows: 0 = no signal, 1 = weak signal, 2 = intermediate signal, and 3 = strong signal. The percentage of the visually determined signal intensity was expressed as follows: 0, 0 %; 1, \<30 %; and 2, \>30 %. The intensity and percentage scores were added to give a final score of 0--5. Expression was determined based on the final score as follows: negative expression, final score ≤ 4; positive expression, 4 \< final score ≤ 5 \[[@R14]\]. MiR-31 expression levels were scored using a previously described ISH scoring system, which combines the signal intensity (0 = no signal, 1 = weak signal, 2 = intermediate signal, and 3 = strong signal) and percentage of positive cells (0, 0 %; 1, \<30 %; and 2, \>30 %) to produce a score that ranges from 0--5. Expression levels were characterized as negative, final score ≤3 or positive, 3 \< final score ≤ 5 \[[@R15]\]. MiR-92a expression levels were scored using the following four-tier scoring system according to the staining intensity: 0 = negative, 1 = weak positive, 2 = moderate and 3 = strong positive. Expression levels were considered as negative, final score ≤ 0.5 or positive 0.5 \< final score ≤ 3 \[[@R16]\]. Cytoplasmic miR-10b staining was categorized as follows: low-expression, \< 20 % of cells stained; high-expression, ≥ 20 % of cells stained \[[@R17]\].

Extraction of miRNAs from FFPE tissue and validation by real time qRT-PCR {#s4_7}
-------------------------------------------------------------------------

FFPE specimens stained with hematoxylin and eosin were identified optimal intratumoral tissue of 192 hepatocellular carcinoma (HCC) patients. Total RNA including miRNA was extracted from FFPE samples using miRNeasy FFPE kit (Qiagen) according to manufacturer\'s instructions. Briefly, the samples were deparaffinsed and lysed with proteinase K digestion. After a short incubation at a higher temperature, DNase treatment was performed to eliminate genomic DNA, including very small DNA fragments which were often present in FFPE samples after long-term fixation and storage. Followed by the addition of buffer RBC and 100% ethanol, then the sample was applied to RNeasy MinElute spin columns. Finally, samples were washed and eluted in RNase free water. RNA concentrations were measured via absorbance spectrophotometry on a NanoVue Plus instrument (GE, General Electric Company).

The expression levels of the candidate miRNAs were validated by real time qRT-PCR. Primers for U6, miR-145, miR-31, miR-92a, and miR-10b were purchased from GeneCopoeia. Real time qRT-PCR was performed by the SYBR Green PCR method using All-in-One™ miR qRT-PCR detection kit (GeneCopoeia, China) with miRNA specific primers. All samples were run in triplicate, and the 2^−ΔΔCt^ method was used to analyse the miRNA expression levels. The qRT-PCR was performed on a 7500 Real-Time PCR System (Applied Biosystems). U6 snRNA was used as the endogenous control.

Statistical analysis {#s4_8}
--------------------

Correlations between clinicopathological features and LNM status were analyzed by Pearson\'s χ^2^ test and Fisher\'s exact test. Then, univariate analysis and multivariate analysis were performed to determine statistically significant variables and devise a simple risk score, which was the corresponding estimated coefficient divided by the minimum χ^2^ value \[[@R18]\]. The final score of every patient was the aggregate of all risk scores. The optimal cutoff point was determined by the χ^2^ test for linear trend for the best separation of LNM risk \[[@R19], [@R20]\]. Prediction performance of the miRNA-based model was evaluated using AUC. The temporal interval from the date of surgery to the date of LNM incidence was considered as time-to-LNM, which was analyzed by Kaplan-Meier and log-rank tests. Cox regression analysis was used to estimate relative LNM risk of the high-risk versus low-risk groups. Two-sided *P* values \< 0.05 were considered as statistically significant. All statistical analyses were conducted with SPSS version 20.0 (SPSS IBM).

SUPPLEMENTARY FIGURE AND TABLES {#s5}
===============================
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